The cancer research community requires a standardized way of describing mathematical and computational models to enable interoperation between systems, repositories, and between the models themselves. In this paper we describe a new markup language, TumorML 1 , for describing computational models that fall within the domain of cancer. TumorML is an XML-based markup language that wraps existing cancer model implementations with metadata for model curation, parametric interface description, implementation description, and compound model linking.
INTRODUCTION
The 'Transatlantic Tumor Model Repositories' project (TU-MOR) aims to develop a European digital cancer model repository [14] , building on past and existing European Commission (EC) projects, to interoperate with the US National Institute of Health/National Cancer Institute (NIH/NCI) semantic-layered cancer research platform, CViT (Center for the Development of a Virtual Tumor) [20] . The ultimate goal is to bridge cancer research communities across the Atlantic through the provision of internationally available data and computing services for cancer modelers, researchers and, ultimately, clinicians to support both basic scientific research in cancer and to develop personalized computer-aided cancer diagnosis and treatment.
Biological model repositories are not novel, as demonstrated by existing open source software such as the Physiome Model Repository [19] , and open data services such as the European Bioinformatics Institute's BioModels Database [12] . However, one of the key aims of TUMOR is to enable a European-based cancer model repository to seamlessly interoperate with its US counterpart, the CViT Digital Model Repository (DMR). As an enabling technological component of the project, a simulation markup language specifically targeted at the cancer modeling domain was developed to act as the standard communication format between elements of Volume 3, Issue 3, Sept 2013 ISSN 2159-1210 the TUMOR infrastructure [15] , and for exporting models externally.
Rationale
We have discussed extensively the need for dealing with diversity in computational cancer modeling [10, 8, 9, 7] . Our requirements are based on the premise that existing biological markup languages are not suited to the immediate needs for state-of-the-art cancer model description. For example, the 'oncosimulator' set of in silico cancer models [16] developed by our colleagues in precursor projects to TU-MOR produce simulations of tumor growth based on a combination of techniques including: nondeterministic finitestate automata, Monte Carlo methods, differential equations to simulate population dynamics of a tumor mass, and pharmacokinetic/pharmacodynamic (PK/PD) interactions with candidate chemical or radiation treatments. Existing markup languages include CellML [5] and SBML (Systems Biology Markup Language) [4] however we deemed both unsuitable for our needs due to lack of expressive notation for statistical models, incorporating random factors necessary in Monte Carlo simulations, or for procedural operations. Oncosimulator models also consider multiple scales in aggregate, covering molecular scale interactions and the clinical perspective using patient histories, description of which cannot be integrated into either CellML or SBML models. Further arguments are described in our 2013 Cancer Informatics commentary [10] .
THE TUMOR MODEL REPOSITORIES MARKUP LANGUAGE
TumorML (Tumor model repositories Markup Language) was developed to overcome the limitations of existing markup languages, not as a competitor to either of CellML and SBML, but to deal with storing and transmitting existing cancer models among research communities. We have previously described the concept and requirements for TumorML [8] and in this paper we present an introduction and highlights of the first published specification of the markup language developed by TUMOR. TumorML has been developed as an XML-based domain-specific vocabulary that includes elements from existing vocabularies to avoid 'reinventing the wheel'. The vocabularies, reused in part, in TumorML version 1.0 include the following:
1. Dublin Core -For basic curation of model description documents and model implementations, we reuse a subset of the Dublin Core Metadata Element Set [11] .
2. xCard -To describe entities that create the model descriptions themselves we use an XML representation of vCards [13] .
3. BibT E XML -Whilst not a standardized XML vocabulary, BibT E XML is a representation of the BibT E X format for bibliographic references [6] . In this first version of TumorML we reuse the document categories with a view to implementing the full BibT E X reference structure in future TumorML versions .
4. JSDL -The Job Description Markup Language (JSDL) provides an established vocabulary for specifying Grid execution jobs, including job execution requirements [1] . A subset of the JSDL execution requirements description is used in TumorML for describing the basic hardware and software requirements in order to run TumorML packaged implementations with a computational framework or batch execution system.
5. xMML -The Multiscale Modeling Language, MML, and its XML version, xMML, proposes a standard way of describing multiscale models and, most significantly, how to couple models of different simulated scales [2] . TumorML version 1.0 reuses a simplified part of the xMML coupling markup to represent the coupling of computational models.
Overview
The full specification of TumorML 1.0 is published as an EC deliverable by TUMOR. In this paper we will describe the main elements and concepts that make up the markup language used in TumorML model description documents. The root element of every TumorML document is <tumorml>, with a <header> and <model> as children. The <header> block contains metadata about the model, and the <model> block description of the model itself in terms of its parametric interface and implementation. A TumorML document follows the general pattern shown in Listing 1:
Listing 1: General pattern of TumorML documents.
Header
The <header> element contains a list of metadata elements to aid in publishing, search and retrieval of TumorML models, and a list of external references to attribute. There may only be one <header> per TumorML document. The header consists of a set of general document curation elements taken from Dublin Core, a set of TUMOR repository specific elements, and a list of references where applicable.
The Dublin Core elements are inherited from the Dublin Core Metadata Element Set, Version 1.1. The TumorML specification does not use the element set exhaustively, but takes key elements including <title>, <creator>, <descrip-tion>, <publisher>, <contributor> and <date>. TumorML true, false also uses a domain-specific taxonomy of models relating to TUMOR that were designed as part of the database schema, summarized in Table 1 , where the schema does not strictly enforce the enumerations, but also allows free text strings to be used. A relevant discussion on the different and diverse types of cancer models has been published by the authors in [10] . A list of <reference> elements describe bibliographic references of models and related components of model descriptions to attribute work done elsewhere that the model description is based on. References have a <ti-tle>, <source> containing a URL, <creator>, full text <ci-tation>, and a <type> that categorizes the reference using BibT E XML categories.
Model
The model element contains the description of a computational model, including its input and output interface, included implementations, and where applicable, compound sub-model topologies. A definition of a model serves as a description of the standard way to interface with the model via exposed parameters (both inputs and outputs), and as a container for any descriptions of model implementations. A model is treated like a 'black box' where the details of the model implementation are of no concern. What is of interest is how to communicate data to and from the model, as well as how to execute an implementation of a model, therefore enabling us to wrap up and publish existing implementations with TumorML.
As described in [8] , models can be either 'simple' or 'complex', and this is reflected in the XML schema by having a choice of two patterns that can be enclosed within the <model> tag. To recap, a simple model description provides a wrapping up of a single computational cancer model, while a complex model describes a compound model; an aggregate of simple or complex models wrapped in TumorML.
A simple model consists of two key descriptors (an example of which shown in the general pattern in Listing 1): an input and output parameter specification, described with a <pa-rameters> block with <in> and <out> elements to define inputs and outputs. Following this, at least one <implementa-tion> block is used to describe a software implementation of the model. In each implementation specification, a description of the files that make up the model is included, as well as a descriptor of how to run the entry point to the packaged files, along with the requirements for execution. A complex model contains the same header elements as a simple model, however under the model description section contained with <model> elements, multiple simple or complex models are referenced within <submodel> elements. Each sub-model is labelled with an identifier that is unique within the root <model> declaration. An additional section is used to define instances of models and a topology of model parameter connections. This is illustrated in Listing 2, where the example shown declares a single sub-model, modelA, with two parameters, and a topology consisting of two instances of modelA connected from instance A's output parameter p2 to instance B's input parameter p1.
Listing 2: Complex model pattern fragment.
<in name="p1"> 6 <value type="double" /> 7 </in> 8 <out name="p2"> 9 <value type="double" /> 10 </out> 11 </parameters> 12 ...
13
</sub-model> 14 <topology> 15 <instance id="A" sub-model="modelA" /> 16 <instance id="B" sub-model="modelA" /> 17 <coupling from="A.p2" to="B.p1" /> 18 </topology> 19 </model>
AN EXAMPLE MODEL
Within TUMOR a number of models contributed by project partners from both the US and EU were wrapped in TumorML markup, including a TumorML complex model description developed using a model from each of the CViT DMR and the EU TUMOR repository, the details of which will be published in a forthcoming paper. We use one of the models taken from the CViT DMR here as an exemplar of how TumorML has been used to wrap up and package an existing model implementation. Wang et al developed a multiscale model for investigating expansion dynamics of non-small cell lung cancer (NSCLC) within a small two-dimensional in silico mesh. At the molecular level, a specific EGFR-ERK intracellular signaling pathway was implemented. Alterations in these molecules are used to trigger phenotypic changes at the cellular level. As described fully in [18] , the authors validated that increasing the amount of available growth factor leads to a spatially more aggressive cancer system, by computationally examining the relationship between extrinsic ligand concentrations, intrinsic molecular profiles and microscopic patterns. The kinetic model of the implemented NSCLC-specific molecular signaling pathway, which consists of 20 protein molecules, is illustrated in Figure 1 . These proteins, including both receptor (epidermal growth factor receptor; EGFR) and nonreceptor kinases, such as PLCγ, have previously been experimentally or clinically proven to play an important role in NSCLC tumorigenesis.
Functionally speaking as a computer-based implementation, the model takes as an input parameter an EGF concentration, simulates both the molecular signalling pathway and interactions between sub cellular molecules as a set of ordinary differential equations (ODEs) to produce as an output the cell cycle duration. This is then used as the basis for simulating the phenotypic changes and consequential proliferation or migration of cells in the two-dimensional mesh over a number of discrete time steps. In the following section we describe the markup used to wrap up the EGFR-ERK pathway model.
Model markup
In the EGFR-ERK pathway example, the metadata is extracted from the corresponding entry taken from the CViT DMR and inserted into a TumorML document under the <header> element. The description element is filled with the text of a short abstract, including references to the relevant published papers about the model itself. Next, stakeholders are described with the main author/developer of the model listed as the model <creator>, the publishing entity in the <publisher> element, in this case the Complex Biosystems Modeling Laboratory at Massachusetts General Hospital, Boston, MA, and finally other associated authors listed under <contributor>. Following a timestamp stored under <date>, we list the TUMOR repository taxonomic elements. In the case of the EGFR-ERK pathway model, the model uses continuous mathematics, is considered to take a bottomUp approach, concerns lung cancer, simulates the cancer as a solid homogenous tumor that is imageable and does not simulate freeGrowth nor treatment.
The model and implementation description is provided under the <model> element. First, the input and output parameters are described to enable the model to be run in an execution environment, like CViT's Computational Model Execution Framework [17] , and linked with other TumorML model descriptions as a complex model. In the case of the EGFR-ERK pathway model here, it is a simple model description as it only concerns the one published implementation.
Under the <parameters> element an input parameter of value type double (double-precision floating point number) is used to represent the EGF concentration, labelled as egf. Two output parameters return the cell cycle time (an estimate average cell cycle time) and PLCγ concentration, both also of type double. The implementation of the model has also been provided under the <implementation> element. In this case a LSID (Life Sciences Identifier [3] ) has been used as the implementation id, the value of which has been taken directly from the CViT DMR. Under the <package> element a URL to the model source code has been provided. Under <command> the command-line interface instruction to execute the model is given. In this case, EGFR_ODE_EC is the executable file, while $egf is the input EGF concentration. Note that the command-line parameter $egf maps directly to egf as defined in the input parameters list earlier. It is assumed the output parameters, as specified in the <parameters> element are written out to a text file each corresponding to the parameter name, in this example i.e. cell cycle time.txt and PLC_g.txt. Note that these input and output parameters map directly to the earlier definition in the <parameters> element, and in turn model the variable inputs and outputs of the actual model as shown in Figure 1 . The internal processing implemented as the set of ODEs is treated as a 'black box' where it is of no concern to the functional description in TumorML. Finally, the minimum requirements for executing a model simulation are specified using standardized vocabulary taken from JSDL. In this case, <operatingSystem> has been specified as Linux, the <CPUArchitecture> as x86 64-bit, and the source code <language> as C++.
CONCLUSIONS
In developing TumorML our success criteria consisted of the following two goals. First, being able to demonstrate the import and export of models between the two repositories preserving as much metadata as possible, and translating between the CViT DMR and TumorML schemas where appropriate. Second, demonstrating a 'transatlantic' combination of models linked together via markup describing each component model's interfaces and their couplings.
Within TUMOR the exchange of models between the CViT DMR and the TUMOR model repository has been demonstrated, one of which, the EGFR-ERK pathway model, is described in this paper. Work towards the construction and execution of a compound model of modules taken from each repository has also been carried out and will be reported in a future publication. However, a greater validation of the markup's usage would be in its adoption by open and public repositories to broaden its currently small community profile. To this end an open-source reference database, supporting TumorML documents natively, is being developed to go alongside the published TumorML schemas to act as a publicly available demonstrator of the markup language.
Volume 3, Issue 3, Sept 2013 ISSN 2159-1210 TumorML is now maintained as open-source software hosted on GitHub (http://www.github.com/tumorml) where we actively invite contributions to its development and community adoption.
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